Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA044691-05
Application #
3558537
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1986-04-01
Project End
1990-06-30
Budget Start
1990-04-12
Budget End
1990-06-30
Support Year
5
Fiscal Year
1990
Total Cost
Indirect Cost

  Institution

Name
University of Maryland Baltimore
Department
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201

  Publications

Lewis, Lionel D; Miller, Antonius A; Owzar, Kouros et al. (2013) The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics 23:29-33
Lewis, Lionel D; Miller, Antonius A; Rosner, Gary L et al. (2007) A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 13:3302-11
Klein, Cheri E; Kastrissios, Helen; Miller, Antonius A et al. (2006) Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol 57:199-206
Miller, Antonius A; Rosner, Gary L; Egorin, Merrill J et al. (2004) Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res 10:8325-31
Akerley, Wallace; Herndon, James E; Egorin, Merrill J et al. (2003) Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 97:2480-6
Rosner, Gary L; Stadler, Walter; Ratain, Mark J (2002) Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 20:4478-84
Fleming, Gini F; Meropol, Neal J; Rosner, Gary L et al. (2002) A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res 8:3718-27
Jodrell, D I; Murray, L S; Hawtof, J et al. (1996) A comparison of methods for limited-sampling strategy design using data from a phase I trial of the anthrapyrazole DuP-941. Cancer Chemother Pharmacol 37:356-62
Kearns, C M; Gianni, L; Egorin, M J (1995) Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22:16-23
Ratain, M J; Rosner, G; Allen, S L et al. (1995) Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol 13:741-7

Showing the most recent 10 out of 20 publications